COVID-19 - April 29, 2021
Valneva initiates Phase 3 trial for VLA2001
Valneva SE has initiated a Phase 3 clinical trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The Phase 3 trial “Cov-Compare”, (VLA2001-301), will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial, states Valneva in a press release. Cov-Compare Approximately 4,000 participants will receive two doses […]
COVID-19 - January 10, 2021
Production and supply – A logistics challenge
The manufacturing, packaging and transportation of COVID-19 vaccines requires a smooth, effective and safe supply chain. Time is of the essence, and the pharma industry supply chain is facing big logistics challenges. In record time the global life science industry has been able to discover and develop one vaccine approved for full use, six vaccines […]
COVID-19 - December 17, 2020
Valneva initiates Phase 1/2 study of its vaccine candidate
Valneva SE has announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001 leverages the manufacturing platform of Valneva’s licensed Japanese encephalitis vaccine, IXIARO and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe. “Our teams have been working extremely hard […]
